Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome.
Tue, 07/03/2017 - 16:45
0 min
Download related document
Select rating
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 1/5
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 2/5
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 3/5
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 4/5
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 5/5
No votes yet
Related
ROVI invests 60 million euros to expand the production capacity of its San...
The Community of Madrid has declared this project to be strategic: it will create 200 new direct jobs for 2027 and raise the plant’s...
4 min
11/07/2024
ROVI forecasts potential Risperidone ISM® sales of between 200 and 300 million...
The company will be submitting for the approval of the Ordinary General Shareholders’ Meeting the annual accounts for the financial...
9 min
24/06/2024
ROVI completes its new Escúzar plant by including a sodium heparin production...
The new facility has meant an investment of 11 million euros This new line, which has now been authorised to commence commercial...
3 min
20/06/2024
See More
Email
Facebook
Twitter
LinkedIn